Beluga Whale’s Drug-Resistant Pneumonia Resolved After Personalized Phage Therapy Delivered Through a Blowhole Nebulizer

The University of Florida has independently confirmed the collaboration through its Emerging Pathogens Institute, which describes the project as work between Mystic Aquarium veterinarian Molly Martony and the laboratory of Daniel Czyz. The university states that the collaboration developed bacteriophage therapy for chronic multidrug-resistant E. coli pneumonia in a beluga and describes the case as having resulted in resolution of the infection. Martony is scheduled to present the case at the University of Florida’s Phage Across One Health Symposium on October 30, 2026.

The most striking aspect of the treatment was not simply the use of bacteriophages, but how they were delivered. Jetta was behaviorally trained to approach the side of her pool three times a day and voluntarily take deep breaths through a nebulizer adapted specifically to fit over a beluga’s blowhole. The device converted the phage preparation into an aerosol that could be inhaled into the respiratory tract. This provided a means of delivering active phages much closer to the infected pulmonary tissues while avoiding the stress and practical difficulty that repeated invasive administration could create in an animal of this size.

For respiratory phage therapy, this distinction is potentially important. When phages are administered systemically, they must circulate through the body, reach the infected tissue at sufficient concentrations and remain biologically active despite distribution, filtration and interactions with the immune system. Aerosolized administration instead attempts to deposit phages directly within the airways. In principle, this can generate high local exposure while reducing the distance between administration and the bacterial population being targeted. Jetta’s treatment does not establish that inhaled administration is universally superior, but it illustrates how route of administration can become a central component of phage pharmacology rather than a secondary technical detail.

Marine mammals present a particularly interesting setting for such an approach. Martony told Popular Science that whales, dolphins and seals are especially susceptible to infections caused by Gram-negative bacteria, including organisms that can become difficult to treat because of antimicrobial resistance. Respiratory infections are also a significant veterinary problem in cetaceans, making the ability to deliver antimicrobials directly through the respiratory route attractive when conventional systemic therapy is insufficient.

The treatment appears to have produced a durable result so far. According to Mystic Aquarium’s veterinary team, Jetta underwent the phage treatment more than a year ago, and subsequent monitoring has found no evidence of recurrence of the E. coli pneumonia. The team has also reported no negative effects attributable to the phage therapy during that follow-up period. These observations are particularly relevant because short-term bacterial suppression would be less convincing in a chronic infection than sustained absence of detectable recurrence.

However, the case has not yet been described in a peer-reviewed scientific publication. The researchers are preparing the work for publication, meaning important technical information is still unavailable publicly. The precise identity and number of phages used, their genomic characterization, bacterial susceptibility measurements, administered titers, complete dosing schedule, whether the nebulized treatment was combined with other routes of phage administration, concurrent antibiotic therapy, microbiological follow-up and criteria used to define resolution have not yet been reported in sufficient detail to independently evaluate the therapeutic contribution of the phages.

This distinction matters because an individual veterinary success cannot establish efficacy in the same way as a controlled clinical study. Chronic infections can fluctuate, antibiotics and supportive treatment may contribute to recovery, and microbiological clearance must be interpreted alongside clinical and imaging findings. Until the complete case is published, the most scientifically accurate description is therefore that personalized phage therapy was associated with resolution of Jetta’s chronic multidrug-resistant E. coli pneumonia after conventional antibiotic treatment had been largely unsuccessful.

The delivery strategy nevertheless deserves particular attention. Nebulized phage therapy is already being investigated in human respiratory medicine because lung infections create several problems for conventional treatment: bacteria may reside in mucus, biofilms and poorly penetrated regions of the respiratory tract, while systemic drug concentrations at these sites may be suboptimal. Aerosol delivery provides a potential route for concentrating active phages within the airways while limiting systemic exposure. The beluga case extends this concept into veterinary medicine and demonstrates that respiratory phage delivery can be integrated into cooperative animal husbandry without repeated restraint or invasive procedures.

The case also illustrates the One Health character of phage therapy. The same underlying problem — bacterial pathogens acquiring resistance faster than conventional treatment options can be developed — occurs in humans, companion animals, livestock, aquaculture and wildlife medicine. The University of Florida’s 2026 Phage Across One Health Symposium explicitly brings together applications across human, animal and agricultural health, and Jetta’s case is being featured as an example of translating phage technology into an unusual veterinary setting.

Daniel Czyz’s University of Florida research program is specifically focused on alternatives to conventional antibiotics and the development of phage-based interventions across One Health sectors. His laboratory has worked on phages targeting several bacterial pathogens and on extending phage applications into veterinary and aquatic medicine. University of Florida material identifies the Jetta collaboration as one of the program’s successful translational examples.

There is also a broader lesson in the way the treatment was designed. Personalized phage therapy depends not only on finding a virus capable of infecting a bacterial isolate but on connecting microbiology, pharmaceutical preparation, dosing and delivery to the actual anatomical site of infection. A highly active phage can fail if it cannot reach its bacterial target at an adequate concentration for sufficient time. Conversely, an appropriate delivery route can potentially transform a microbiologically active phage into a clinically useful intervention.

Jetta’s blowhole nebulizer makes that principle unusually visible. Rather than adapting the animal to a conventional medical delivery system, veterinarians adapted the delivery system to the animal. Training the beluga to voluntarily inhale an aerosolized preparation allowed repeated respiratory administration while minimizing stress, a consideration that is both clinically relevant and particularly important in zoological medicine.

Several questions will become important when the full scientific report is released. It will be necessary to determine how the E. coli strain was characterized, how candidate phages were selected, whether one phage or a cocktail was used, how resistance was monitored, what phage concentrations reached the respiratory tract, whether viable phages could be recovered after nebulization, and how treatment affected bacterial cultures, pulmonary imaging and clinical respiratory parameters over time.

It will also be important to know whether nebulization altered phage viability. Aerosolization exposes viral particles to mechanical and physicochemical stresses that can vary substantially with nebulizer design, particle size and formulation. Different phages can respond very differently to these conditions. Demonstrating that infectious titers remain adequate after nebulization is therefore essential when translating an apparently simple delivery method into a reproducible therapeutic platform.

The case should consequently be viewed neither as proof that phage therapy can replace antibiotics in marine mammals nor merely as an unusual veterinary anecdote. It is an early translational example showing how personalized phage selection and site-directed delivery may be combined when a difficult bacterial infection is no longer responding adequately to conventional treatment.

More than a year without reported recurrence makes the outcome particularly noteworthy, while the forthcoming scientific publication should provide the data needed to determine exactly how much of that outcome can be attributed to bacteriophage therapy and which elements of the protocol could be reproduced in other animals.

If those details support the preliminary report, Jetta’s treatment could become an important case study not only for marine mammal medicine but also for the broader development of inhaled phage therapy. It demonstrates a central principle increasingly emerging across the field: finding the right phage may be only half of the problem. Getting viable phages to the right place, at the right concentration and for long enough to control the infection may be just as important.

Sources :

Margherita Bassi. Blowhole nebulizer helps cure beluga whale’s pneumonia. Popular Science, September 24, 2026.
https://www.popsci.com/environment/blowhole-nebulizer-beluga-whale-pneumonia/

University of Florida Emerging Pathogens Institute. Phage Across One Health Symposium, October 30, 2026.
https://epi.ufl.edu/events/phage-across-one-health-symposium/

Reinventing the fight against bacteria,
one phage at a time.

Our Tools